Advances in methotrexate nano-formulations to enhance therapeutic efficacy against drug-resistant breast cancer
Source abstract
Abstract
Methotrexate (MTX), a widely used chemotherapeutic agent and folate antagonist, is commonly employed in the treatment of various cancers and immune-mediated inflammatory diseases. However, conventional MTX therapy is associated with several limitations, including intestinal mucositis, high systemic toxicity, low bioavailability, poor pharmacokinetics, and a short half-life. To overcome these drawbacks, recent advances have focused on encapsulating MTX within nanoparticles (NPs) or polymer-based systems, which enhance sustained drug release, reduce toxicity and improve therapeutic efficacy. This review highlights various MTX-based nano-delivery systems developed for breast cancer treatment, including gold NPs, mesoporous silica NPs, lipid–polymer hybrid NPs, chitosan NPs, magnetic alginate NPs, iron oxide magnetic NPs, and carbon nanotubes. Preclinical studies on targeted delivery approach utilizing these nanocarriers has demonstrated reduced systemic toxicity and improved treatment outcomes in breast cancer models. This highlights the need for more research focused on clinical trials and combination therapies to further enhance therapeutic benefits.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Oral health in cancer treatment · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485–505.10.1200/JCO.20.03399 ↗
2. Chen Z, Cai Z, Zhu C, Song X, Qin Y, Zhu M, Zhang T, Cui W, Tang H, Zheng H. Injectable and self-healing hydrogel with anti‐bacterial and anti‐inflammatory properties for acute bacterial rhinosinusitis with micro invasive treatment. Adv Healthc Mater. 2020;9(20):2001032.10.1002/adhm.202001032 ↗
3. Liem GS, Mo FKF, Pang E, Suen JJS, Tang NLS, Lee KM, Yip CHW, Tam WH, Ng R, Koh J. Chemotherapy-related amenorrhea and menopause in young Chinese breast cancer patients: analysis on incidence, risk factors and serum hormone profiles. PLoS ONE. 2015;10(10):e0140842.10.1371/journal.pone.0140842 ↗
4. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology. 2010;115(2):155–62.10.1159/000265166 ↗
5. Hutchinson SA, Websdale A, Cioccoloni G, Røberg-Larsen H, Lianto P, Kim B, Rose A, Soteriou C, Pramanik A, Wastall LM. Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer. Oncogene. 2021;40(16):2872–83.10.1038/s41388-021-01720-w ↗
6. Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. In: Breast cancer chemosensitivity. Berlin: Springer; 2007. pp. 23–30.10.1007/978-0-387-74039-3_2 ↗
7. Romero-Garcia S, Prado-Garcia H, Carlos-Reyes A. Role of DNA methylation in the resistance to therapy in solid tumors. Front Oncol. 2020;10:1152.10.3389/fonc.2020.01152 ↗
8. Choi C-H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005;5:1–13.10.1186/1475-2867-5-30 ↗
9. Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci. 2005;96(8):457–65.10.1111/j.1349-7006.2005.00081.x ↗
10. Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT. Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol. 2003;14(6):833–42.10.1093/annonc/mdg260 ↗
11. Brown JI, Persaud R, Iliev P, Karmacharya U, Attarha S, Sahile H, Olsen JE, Hanke D, Idowu T, Frank DA. Investigating the anti-cancer potential of pyrimethamine analogues through a modern chemical biology lens. Eur J Med Chem. 2024;264:115971.10.1016/j.ejmech.2023.115971 ↗
12. Wu J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Personal. Med. 2021;11(8):771.10.3390/jpm11080771 ↗
13. Pramanik A, Laha D, Pramanik P, Karmakar P. A novel drug copper acetylacetonate loaded in folic acid-tagged chitosan nanoparticle for efficient cancer cell targeting. J Drug Target. 2014;22(1):23–33.10.3109/1061186X.2013.832768 ↗
14. Pramanik A, Laha D, Dash SK, Chattopadhyay S, Roy S, Das DK, Pramanik P, Karmakar P. An in-vivo study for targeted delivery of copper-organic complex to breast cancer using chitosan polymer nanoparticles. Mater Sci Eng C. 2016;68:327–37.10.1016/j.msec.2016.05.014 ↗
15. Chaudhari R, Patel P, Meghani N, Nasra S, Kumar A. Fabrication of methotrexate-loaded gold nanoconjugates and its enhanced anticancer activity in breast cancer. 3 Biotech. 2021;11(4):175.10.1007/s13205-021-02718-7 ↗
16. Rani R, Malik P, Dhania S, Mukherjee TK. Recent advances in mesoporous silica nanoparticle-mediated drug delivery for breast cancer treatment. Pharmaceutics. 2023;15(1):227.10.3390/pharmaceutics15010227 ↗
17. Ekinci M, Ilem-Ozdemir D, Gundogdu E, Asikoglu M. Methotrexate loaded chitosan nanoparticles: preparation, radiolabeling and in vitro evaluation for breast cancer diagnosis. J Drug Deliv Sci Technol. 2015;30:107–13.10.1016/j.jddst.2015.10.004 ↗
18. Torres-Perez SA, Ramos-Godínez MdelP, Ramon-Gallegos E. Glycosylated one-step PAMAM dendrimers loaded with methotrexate for target therapy in breast cancer cells MDA-MB-231. J Drug Deliv Sci Technol. 2020;58:101769.10.1016/j.jddst.2020.101769 ↗
19. Taran Z, Digehsaraei SY, Salouti M, Amini B, Mahmazi S, Kalantari M. Methotrexate loaded in alginate beads for controlled drug release against breast cancer. Gene. 2023;851:146941.10.1016/j.gene.2022.146941 ↗
20. Shabnum SS, Siranjeevi R, Raj CK, Nivetha P, Benazir K. A comprehensive review on recent progress in carbon nanotubes for biomedical application. Environ Qual Manag. 2025;34(3):e70040.10.1002/tqem.70040 ↗
21. Estelrich J, Escribano E, Queralt J, Busquets MA. Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery. Int J Mol Sci. 2015;16(4):8070–101.10.3390/ijms16048070 ↗
22. Tahir N, Madni A, Balasubramanian V, Rehman M, Correia A, Kashif PM, Mäkilä E, Salonen J, Santos HA. Development and optimization of methotrexate-loaded lipid-polymer hybrid nanoparticles for controlled drug delivery applications. Int J Pharm. 2017;533(1):156–68.10.1016/j.ijpharm.2017.09.061 ↗
23. Jain A, Jain SK. Methotrexate-loaded hybrid nanoparticles for improved pharmacokinetics and enhanced anticancer activity in breast cancer therapy. Int J Pharm. 2019;567:118480. https://doi.org/10.1016/j.ijpharm.2019.118480.10.1016/j.ijpharm.2019.118480 ↗
24. Garg NK, Singh B, Jain A, Nirbhavane P, Sharma R, Tyagi RK, Kushwah V, Jain S, Katare OP. Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics. Colloids Surf B. 2016;146:114–26.10.1016/j.colsurfb.2016.05.051 ↗
25. Upadhyay S, Soni G. Design, Optimization and Characterization of Methotrexate Solid Lipid Nanoparticles for the Effective Management of Rheumatoid Arthritis. Scopus Index [Internet]. 2025;18(2):7946–57. https://doi.org/10.37285/ijpsn.2025.18.2.6.10.37285/ijpsn.2025.18.2.6 ↗
26. Muntoni E, Martina K, Marini E, Giorgis M, Lazzarato L, Salaroglio IC, Riganti C, Lanotte M, Battaglia L. Methotrexate-loaded solid lipid nanoparticles: Protein functionalization to improve brain biodistribution. Pharmaceutics. 2019;11(2):65.10.3390/pharmaceutics11020065 ↗
27. Maiti D, Inamdar MN, Almuqbil M, Suresh S, Asdaq SMB, Alshehri S, Al Arfaj SA, Alamri AM, Aldohyan MM, Alqahtani MT. Evaluation of solid-lipid nanoparticles formulation of methotrexate for anti-psoriatic activity. Saudi Pharm J. 2023;31(6):834–44.10.1016/j.jsps.2023.04.007 ↗
28. Ali EMM, Hussein MA, Abdel-Magied AF. Methotrexate loaded chitosan-coated magnetite nanoparticles as a targeted drug delivery system for breast cancer therapy. Int J Biol Macromol. 2018;120:1170–80. https://doi.org/10.1016/j.ijbiomac.2018.08.110.10.1016/j.ijbiomac.2018.08.110 ↗
29. Agabeigi R, Rasta SH, Rahmati-Yamchi M, Salehi R, Alizadeh E. Novel chemo-photothermal therapy in breast cancer using methotrexate-loaded folic acid conjugated Au@ SiO2 nanoparticles. Nanoscale Res Lett. 2020;15(1):62.10.1186/s11671-020-3295-1 ↗
30. Chaudhari RG, Taware SD, Patil SB. Fabrication of methotrexate-gold nanoparticle conjugates and evaluation of anticancer activity in breast cancer cells. Sci Rep. 2021;11:9050. https://doi.org/10.1038/s41598-021-88561-w.10.1038/s41598-021-88561-w ↗
31. Raut J, Sarkar O, Das T, Mandal SM, Chattopadhyay A, Sahoo P. Efficient delivery of methotrexate to MDA-MB-231 breast cancer cells by a pH-responsive ZnO nanocarrier. Sci Rep. 2023;13(1):21899.10.1038/s41598-023-49464-9 ↗
32. Aliabadi A, Ramezani M, Sheikhi-Mohammareh S, Abnous K, Taghdisi SM, Alibolandi M. Synthesis of glutathione-responsive, amphiphilic methotrexate-based prodrug nanoparticles: In vitro and in vivo assessment against metastatic breast cancer. Int J Pharm. 2025;686:126293. https://doi.org/10.1016/j.ijpharm.2025.126293.10.1016/j.ijpharm.2025.126293 ↗
33. Elfadele MM. pH-responsive methotrexate-loaded bilosomes enhance apoptosis and anticancer activity in breast cancer cells. Drug Deliv. 2021;28(1):1974–86. https://doi.org/10.1080/10717544.2021.1985884.10.1080/10717544.2021.1985884 ↗
34. Huang A, Zhao X, Yang X-R, Li F-Q, Zhou X-L, Wu K, Zhang X, Sun Q-M, Cao Y, Zhu H-M. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. J Hepatol. 2017;67(2):293–301.10.1016/j.jhep.2017.03.005 ↗
35. Luo Q, Lin T, Zhang CY, Zhu T, Wang L, Ji Z, Jia B, Ge T, Peng D, Chen W. A novel glyceryl monoolein-bearing cubosomes for gambogenic acid: preparation, cytotoxicity and intracellular uptake. Int J Pharm. 2015;493(1–2):30–9.10.1016/j.ijpharm.2015.07.036 ↗
36. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008;14(13):4200–5.10.1158/1078-0432.CCR-07-4592 ↗
37. Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Deliv. 2012;2012(1):581363.
38. Guan M, Ge J, Wu J, Zhang G, Chen D, Zhang W, Zhang Y, Zou T, Zhen M, Wang C. Fullerene/photosensitizer nanovesicles as highly efficient and clearable phototheranostics with enhanced tumor accumulation for cancer therapy. Biomaterials. 2016;103:75–85.10.1016/j.biomaterials.2016.06.023 ↗
39. Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, Wang YW, Yeh CG, Chiang NJ, Chang JY. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015;75:579–86.10.1007/s00280-014-2671-x ↗
40. Wang D, Zhao P, Lu T, Ren J, Zhu L, Han X, Zhang G, Dong X, Ma H, Yu M. ctDNA as a prognostic biomarker in resectable CLM: systematic review and meta-analysis. Open Life Sci. 2023;18(1):20220615.10.1515/biol-2022-0615 ↗
41. Yarden RI, Wilson MA, Chrysogelos SA. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem. 2001;81(S36):232–46.10.1002/jcb.1142 ↗
42. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–34.10.1016/j.cell.2010.06.011 ↗
43. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37:9–15.10.1016/S0959-8049(01)00231-3 ↗
44. Crown J, O’Leary M. The taxanes: an update. Lancet. 2000;355(9210):1176–8.10.1016/S0140-6736(00)02074-2 ↗
45. Shimada T, Ueda M, Jinno H, Chiba N, Wada M, Watanabe J, Ishihara K, Kitagawa Y. Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. Anticancer Res. 2009;29(4):1009–14.
46. McLean L, Soto U, Agama K, Francis J, Jimenez R, Pommier Y, Sowers L, Brantley E. Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells. Int J Cancer. 2008;122(7):1665–74.10.1002/ijc.23244 ↗
47. Brinkman AM, Wu J, Ersland K, Xu W. Estrogen receptor α and aryl hydrocarbon receptor independent growth inhibitory effects of aminoflavone in breast cancer cells. BMC Cancer. 2014;14:1–16.10.1186/1471-2407-14-344 ↗
48. Jahan S, Karim ME, Chowdhury EH. Nanoparticles targeting receptors on breast cancer for efficient delivery of chemotherapeutics. Biomedicines. 2021;9(2):114.10.3390/biomedicines9020114 ↗
49. Brinkman AM, Chen G, Wang Y, Hedman CJ, Sherer NM, Havighurst TC, Gong S, Xu W. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. Biomaterials. 2016;101:20–31.10.1016/j.biomaterials.2016.05.041 ↗
50. Kurmi BD, Patel P, Paliwal R, Paliwal SR. Molecular approaches for targeted drug delivery towards cancer: a concise review with respect to nanotechnology. J Drug Deliv Sci Technol. 2020;57:101682.10.1016/j.jddst.2020.101682 ↗
51. Sabharanjak S, Mayor S. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev. 2004;56(8):1099–109.10.1016/j.addr.2004.01.010 ↗
52. Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updates. 2014;17(4–6):89–95.10.1016/j.drup.2014.10.002 ↗
53. Boogerd LSF, Boonstra MC, Beck A-J, Charehbili A, Hoogstins CES, Prevoo HAJM, Singhal S, Low PS, van de Velde CJH, Vahrmeijer AL. Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients. Oncotarget. 2016;7(14):17442.10.18632/oncotarget.7856 ↗
54. Elnakat H. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004;56(8):1067–84.10.1016/j.addr.2004.01.001 ↗
55. Soe ZC, Thapa RK, Ou W, Gautam M, Nguyen HT, Jin SG, Ku SK, Oh KT, Choi H-G, Yong CS. Folate receptor-mediated celastrol and irinotecan combination delivery using liposomes for effective chemotherapy. Colloids Surf B. 2018;170:718–28.10.1016/j.colsurfb.2018.07.013 ↗
56. Lucky SS, Soo KC, Zhang Y. Nanoparticles in photodynamic therapy. Chem Rev. 2015;115(4):1990–2042.10.1021/cr5004198 ↗
57. Boge L, Hallstensson K, Ringstad L, Johansson J, Andersson T, Davoudi M, Larsson PT, Mahlapuu M, Håkansson J, Andersson M. Cubosomes for topical delivery of the antimicrobial peptide LL-37. Eur J Pharm Biopharm. 2019;134:60–7.10.1016/j.ejpb.2018.11.009 ↗
58. Gilbert IH. Inhibitors of dihydrofolate reductase in leishmania and trypanosomes. Biochim Biophys Acta BBA Mol Basis Dis. 2002;1587(2–3):249–57.10.1016/S0925-4439(02)00088-1 ↗
59. Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metabol. 2017;25(1):27–42.10.1016/j.cmet.2016.08.009 ↗
60. Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Jt Bone Spine. 2019;86(3):301–7.10.1016/j.jbspin.2018.07.004 ↗
61. Abbasi IHR, Abbasi F, Wang L, Abd El Hack ME, Swelum AA, Hao R, Yao J, Cao Y. Folate promotes S-adenosyl methionine reactions and the microbial methylation cycle and boosts ruminants production and reproduction. Amb Express. 2018;8:1–10.10.1186/s13568-018-0592-5 ↗
62. Avraham A, Cho SS, Uhlmann R, Polak ML, Sandbank J, Karni T, Pappo I, Halperin R, Vaknin Z, Sella A. Tissue specific DNA methylation in normal human breast epithelium and in breast cancer. PLoS ONE. 2014;9(3):e91805.10.1371/journal.pone.0091805 ↗
63. Vietri MT, D’Elia G, Benincasa G, Ferraro G, Caliendo G, Nicoletti GF, Napoli C. DNA methylation and breast cancer: a way forward. Int J Oncol. 2021;59(5):1–12.10.3892/ijo.2021.5278 ↗
64. Christensen BC, Kelsey KT, Zheng S, Houseman EA, Marsit CJ, Wrensch MR, Wiemels JL, Nelson HH, Karagas MR, Kushi LH. Breast cancer DNA methylation profiles are associated with tumor size and alcohol and folate intake. PLoS Genet. 2010;6(7):e1001043.10.1371/journal.pgen.1001043 ↗
65. Liu L, An X, Schaefer M, Yan B, de la Torre C, Hillmer S, Gladkich J, Herr I. Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death. Biomed Pharmacother. 2022;153:113511.10.1016/j.biopha.2022.113511 ↗
66. Chen Y, Fang H, Sun H, Wu X, Xu Y, Zhou B-BS, Li H. Up-regulation of ABCG1 is associated with methotrexate resistance in acute lymphoblastic leukemia cells. Front Pharmacol. 2024;14:1331687.10.3389/fphar.2023.1331687 ↗
67. Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res therapy. 2007;9:1–9.10.1186/ar2187 ↗
68. Levick JR. Microvascular architecture and exchange in synovial joints. Microcirculation. 1995;2(3):217–33.10.3109/10739689509146768 ↗
69. Halin C, Neri D. Antibody-based targeting of angiogenesis. Crit Rev Ther Drug Carrier Syst. 2001;18(3):299–339.10.1615/CritRevTherDrugCarrierSyst.v18.i3.20 ↗
70. Stehle G, Wunder A, Schrenk HH, Hartung G, Heene DL, Sinn H. Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats. Anticancer Drugs. 1999;10(4):405–12.10.1097/00001813-199904000-00009 ↗
71. Kimmick GG, Cirrincione C, Duggan DB, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson IC, Hudis C. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat. 2009;113:479–90.10.1007/s10549-008-9943-2 ↗
72. Sezer AD. Application of nanotechnology in drug delivery. BoD–Books on Demand; 2014.10.5772/57028 ↗
73. Åslund AKO, Vandebriel RJ, Caputo F, De Jong WH, Delmaar C, Hyldbakk A, Rustique E, Schmid R, Snipstad S, Texier I. A comparative biodistribution study of polymeric and lipid-based nanoparticles. Drug Deliv Transl Res. 2022;12(9):2114–31.10.1007/s13346-022-01157-y ↗
74. Jang J-H, Jeong S-H, Lee Y-B. Preparation and in vitro/in vivo characterization of polymeric nanoparticles containing methotrexate to improve lymphatic delivery. Int J Mol Sci. 2019;20(13):3312.10.3390/ijms20133312 ↗
75. Shen J, Burgess DJ. vitro dissolution testing strategies for nanoparticulate drug delivery systems: recent developments and challenges. Drug Deliv Transl Res. 2013;3:409–15.10.1007/s13346-013-0129-z ↗
76. Murawala P, Tirmale A, Shiras A, Prasad BLV. In situ synthesized BSA capped gold nanoparticles: effective carrier of anticancer drug methotrexate to MCF-7 breast cancer cells. Mater Sci Eng C. 2014;34:158–67.10.1016/j.msec.2013.09.004 ↗
77. Shakeran Z, Varshosaz J, Keyhanfar M, Mohammad-Beigi H, Rahimi K, Sutherland DS. Co-delivery of STAT3 siRNA and methotrexate in breast cancer cells. Artif Cells Nanomed Biotechnol. 2022;50(1):29–39.10.1080/21691401.2022.2030746 ↗
78. Alidadiyani N, Salehi R, Ghaderi S, Samadi N, Davaran S. Synergistic antiproliferative effects of methotrexate-loaded smart silica nanocomposites in MDA-MB-231 breast cancer cells. Artif Cells Nanomed Biotechnol. 2016;44(2):603–9.10.3109/21691401.2014.975235 ↗
79. Shakeran Z, Keyhanfar M, Varshosaz J, Sutherland DS. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment. Mater Sci Eng C. 2021;118:111526.10.1016/j.msec.2020.111526 ↗
80. Garg NK, Tyagi RK, Sharma G, Jain A, Singh B, Jain S, Katare OP. Functionalized lipid–polymer hybrid nanoparticles mediated codelivery of methotrexate and aceclofenac: a synergistic effect in breast cancer with improved pharmacokinetics attributes. Mol Pharm. 2017;14(6):1883–97.10.1021/acs.molpharmaceut.6b01148 ↗
81. Garg NK, Singh B, Sharma G, Kushwah V, Tyagi RK, Jain S, Katare OP. Development and characterization of single step self-assembled lipid polymer hybrid nanoparticles for effective delivery of methotrexate. RSC Adv. 2015;5(77):62989–99.10.1039/C5RA12459J ↗
82. Al-Nemrawi N, Hameedat F, Al-Husein B, Nimrawi S. Photolytic controlled release formulation of methotrexate loaded in chitosan/TiO2 nanoparticles for breast cancer. Pharmaceuticals. 2022;15(2):149.10.3390/ph15020149 ↗
83. Nosrati H, Salehiabar M, Davaran S, Danafar H, Manjili HK. Methotrexate-conjugated L-lysine coated iron oxide magnetic nanoparticles for inhibition of MCF-7 breast cancer cells. Drug Dev Ind Pharm. 2018;44(6):886–94.10.1080/03639045.2017.1417422 ↗
84. Attari E, Nosrati H, Danafar H, Kheiri H, Manjili. Methotrexate anticancer drug delivery to breast cancer cell lines by iron oxide magnetic based nanocarrier. J Biomed Mater Res Part A. 2019;107(11):2492–500.10.1002/jbm.a.36755 ↗
85. Bhattacharya D, Mukhopadhyay M, Shivam K, Tripathy S, Patra R, Pramanik A. Recent developments in photodynamic therapy and its application against multidrug resistant cancers. Biomed Mater. 2023;18:062005.10.1088/1748-605X/ad02d4 ↗
86. Karimi A, Erfan M, Mortazavi SA, Ghorbani-Bidkorbeh F, Landi B, Kobarfard F, Shirazi FH. The photothermal effect of targeted methotrexate-functionalized multi-walled carbon nanotubes on MCF7 cells. Iran J Pharm Res. 2019;18(Suppl1):e124458. https://doi.org/10.22037/ijpr.2020.14484.12423.10.22037/ijpr.2020.14484.12423 ↗
87. Samorì C, Ali-Boucetta H, Sainz R, Guo C, Toma FM, Fabbro C, Da Ros T, Prato M, Kostarelos K, Bianco A. Enhanced anticancer activity of multi-walled carbon nanotube–methotrexate conjugates using cleavable linkers. Chem Commun. 2010;46(9):1494–6.10.1039/B923560D ↗
88. Kus-Liśkiewicz M, Fickers P, Ben Tahar I. Biocompatibility and cytotoxicity of gold nanoparticles: recent advances in methodologies and regulations. Int J Mol Sci. 2021;22(20):10952.10.3390/ijms222010952 ↗
89. Kong F-Y, Zhang J-W, Li R-F, Wang Z-X, Wang W-J, Wang W. Unique roles of gold nanoparticles in drug delivery, targeting and imaging applications. Molecules. 2017;22(9):1445.10.3390/molecules22091445 ↗
90. Tyagi T, Solanki R, Patel S, Maity P. Synthesis of methotrexate-conjugated BSA-stabilized gold nanoclusters for improved anticancer efficacy in lung and breast cancer cells. Next Res. 2025;2:100984. https://doi.org/10.1016/j.nexres.2025.100984.10.1016/j.nexres.2025.100984 ↗
91. Agabeigi R, Rasta SH, Rahmati-Yamchi M, Salehi R, Alizadeh E. Novel chemo-photothermal therapy in breast cancer using methotrexate-loaded folic acid conjugated Au@ SiO2 nanoparticles. Nanoscale Res Lett. 2020;15:1–14.10.1186/s11671-020-3295-1 ↗
92. Broadbent M, Chadwick SJ, Brust M, Volk M. Gold nanoparticles for photothermal and photodynamic therapy. ACS omega. 2024;9(44):44846–59.10.1021/acsomega.4c08797 ↗
93. Camacho SA, Aoki PHB, Ekstrand F, Oliveira ON Jr, Prinz CN. Enhancing photothermal therapy against breast cancer cells by modulating the end point of gold shell-isolated nanoparticles using nanostraw-assisted injection. ACS Appl Mater Interfaces. 2025;17(19):27816–28.10.1021/acsami.5c00084 ↗
94. Dutta Gupta Y, Mackeyev Y, Krishnan S, Bhandary S. Mesoporous silica nanotechnology: promising advances in augmenting cancer theranostics. Cancer Nanotechnol. 2024;15(1):9.10.1186/s12645-024-00250-w ↗
95. Branda F, Costantini A, Luciani G, Silvestri B. Smart nanoparticles for cancer therapy. AICIng 2012 VIII Convegno Nazionale dell’Associazione di Chimica per Ingegneria; 2012.
96. Ahmadi F, Sodagar-Taleghani A, Ebrahimnejad P, Moghaddam SPH, Ebrahimnejad F, Asare-Addo K, Nokhodchi A. A review on the latest developments of mesoporous silica nanoparticles as a promising platform for diagnosis and treatment of cancer. Int J Pharm. 2022;625:122099.10.1016/j.ijpharm.2022.122099 ↗
97. Abbas AY, Sulaiman GM, Khan RA, Mohammed HA. Hesperidin-methotrexate dual drugs-loaded mesoporous silica nanoparticles: dose reductions, bioavailability increments, and enhanced anti-cancer activity with organs safety. Inorg Chem Commun. 2025;181:115127.10.1016/j.inoche.2025.115127 ↗
98. Mikušová V, Mikuš P. Advances in chitosan-based nanoparticles for drug delivery. Int J Mol Sci. 2021;22(17):9652.10.3390/ijms22179652 ↗
99. Guadarrama-Escobar OR, Serrano-Castañeda P, Anguiano-Almazán E, Vázquez-Durán A, Peña-Juárez MC, Vera-Graziano R, Morales-Florido MI, Rodriguez-Perez B, Rodriguez-Cruz IM, Miranda-Calderón JE, Escobar-Chávez JJ. Chitosan nanoparticles as oral drug carriers. Int J Mol Sci. 2023;24(5):4289.10.3390/ijms24054289 ↗
100. Karimian-Shaddel A, Dadashi H, Mashinchian M, Mohabbat A, Nazemiyeh AR, Vandghanooni S, Eskandani M. Codelivery of metformin and methotrexate with optimized chitosan nanoparticles for synergistic triple-negative breast cancer therapy in vivo. Int J Pharm. 2024;667:124897. https://doi.org/10.1016/j.ijpharm.2024.124897.10.1016/j.ijpharm.2024.124897 ↗